home / stock / otlc / otlc news

OTLC News and Press, Oncotelic Therapeutics Inc From 09/14/22

Stock Information
Company Name: Oncotelic Therapeutics Inc
Stock Symbol: OTLC
Market: OTC
Website: oncotelic.com
Menu
OTLC OTLC Quote OTLC Short OTLC News OTLC Articles OTLC Message Board
Get OTLC Alerts

News, Short Squeeze, Breakout and More Instantly...
OTLC - Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), developer of treatments for rare and orphan indications, including Parkinson Disease and DIPG, today announced that th...
OTLC - Oncotelic Therapeutics reports Q2 results

Oncotelic Therapeutics press release ( OTCQB:OTLC ): Q2 Net profit of $15.97M “With the JV transaction, commencing Q2 2022, we have recorded a one-time profit of approximately $16 million, primarily on the gain on transfer of OT-101 to the JV of approximately $17.0 mill...

OTLC - ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS

Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 million Reduction in expenses in Q2 2022 versus Q2 2021 by over $3.5M, AGOURA HILLS, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (...

OTLC - Oncotelic Participating at Biotechgate Digital Partnering

AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that th...
OTLC - Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer

AGOURA HILLS, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced tha...

OTLC - Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention

AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced tha...

OTLC - Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal

Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in a $125 million agreement. Oncotelic Therapeutics, a South San Francisco company, formed a Hong Kong JV with Dragon Overseas Capital to develop TGF-β therapeutics. ...
OTLC - Oncotelic gets FDA nod for mid-stage trial design for lead asset and Keytruda combo

Clinical-stage biotech Oncotelic Therapeutics (OTCQB:OTLC) announced on Wednesday that the Food and Drug Administration (FDA) cleared the Phase 2 trial protocol for the company’s lead candidate OT-101 in combination with Merck’s (MRK) Keytruda in mesothelioma. The company plans ...

OTLC - Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)

AGOURA HILLS, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced the cl...

OTLC - Mateon Therapeutics reports Q1 results

Mateon Therapeutics press release (OTCQB:OTLC): Q1 net loss of $5.09M. For further details see: Mateon Therapeutics reports Q1 results

Previous 10 Next 10